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Key messages: 
 PMR and GCA are strongly correlated with age with disease prevalence set to rise. 
 PMR and GCA share common risk factors with vascular disease suggesting a common 
underlying propensity. 
 Pre-existing cardiovascular risk factors need to be taken into account in studies of disease 
aetiology.   
Abstract 
Objectives 
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are associated with increased risk of 
vascular disease. However, it remains unclear whether this relationship is causal or reflects a 
common underlying propensity.  The aim of this study was to identify whether known cardiovascular 
risk factors increase the risk of PMR and GCA.  
Methods 
Clinical records were examined using key word searches to identify cases of PMR and GCA, applying 
current classification criteria in a population-based cohort. Associations between cardiovascular risk 
factors and incident PMR and GCA were analysed using Cox proportional hazards. 
Results 
In 315,022 person years of follow-up, there were 395 incident diagnoses of PMR and 118 incident 
diagnoses of GCA which met the clinical definition. Raised diastolic blood pressure (>90 mm/Hg) at 
baseline /recruitment was associated with subsequent incident PMR (HR = 1.35 (1.01, 1.80) 
p=0.045), and ever-smoking was associated with incident GCA (HR = 2.01 (1.26, 3.20) p=0.003). 
Estimates were similar when the analysis was restricted to individuals whose diagnoses satisfied the 
current classification criteria sets.  
Conclusion 
PMR and GCA shares common risk factors with vascular disease onset, suggesting a common 
underlying propensity. This may indicate a potential for disease prevention strategies through 
modifying cardiovascular risk. 
Introduction 
Cohort and case-control studies have reported associations between vascular end-points and PMR 
and GCA, but it remains unclear whether the association is a consequence of disease or reflects a 
common underlying propensity (1-4). The aetiology of PMR and GCA is unknown but may be 
explained partly through a mechanism of endothelial dysfunction and chronic inflammation, which 
in turn may be shared with vascular disease (5, 6).  
Few studies have investigated the aetiological contribution of traditional cardiovascular disease risk 
factors to PMR or GCA disease onset, and their results have been conflicting. Some case-control 
studies found associations between smoking and GCA, but their findings were not replicated in a 
recent cohort study from Iceland in which smoking was found to be protective against the onset of 
GCA (7-10).   
The aim of this study was to investigate the aetiological contribution of cardiovascular disease risk 
factors to incident diagnoses of PMR and GCA, using data from a large community-based cohort 





Individuals were recruited to the European Prospective Investigation into Cancer and Nutrition 
(EPIC) Norfolk cohort study from 35 GP practices across rural, suburban and inner-city areas of 
Norfolk UK.  A total of 25,639 men and women aged 40-79 years were recruited at baseline between 
the years 1993-1997.  
PMR and GCA case assignment and definition 
Diagnoses of PMR and GCA were identified amongst participants in EPIC-Norfolk in the following 
ways: (i) free text questionnaire responses at baseline, 18 months, three, ten and thirteen years 
follow-up; (ii) linked hospital electronic discharge summaries containing ICD disease codes (iii) out-
patient clinic letter key word searches.  All cases were diagnosed by either primary or secondary care 
based physicians, were aged 50 years and over at time of diagnosis and treated with glucocorticoids.  
This method of case ascertainment has been validated in the Clinical Practice Research Datalink 
(CPRD).  Case assignment was carried out independently by two rheumatologists (MY, RW).  All 
diagnostic tests and case records were scrutinised for all diagnoses and to apply current 
classification criteria.  Analysis was restricted to incident diagnoses of PMR and GCA, namely those 
cases that developed after the date of enrolment into the cohort. Individuals with coexisting 
diagnoses of PMR and GCA were classified as having GCA for the purpose of analysis.  Participants 
diagnosed within 12 months of enrolment were excluded from analysis. The end date of the 
observation period was 31st March 2015.  
Covariates 
Participants completed validated health and lifestyle questionnaires at inclusion and attended nurse-
led health checks at enrolment.  These assessments captured information on blood pressure, 
measures of cholesterol metabolism (triglycerides, high- and low-density lipoprotein, total 
cholesterol), smoking status, and presence of antecedent diabetes mellitus, and high-sensitivity C-
reactive protein (hs-CRP).  Blood samples used for measurement of CRP at baseline were centrifuged 
at 2,100 g for 15 min at 4 °C and then kept frozen in −80 °C freezers until being thawed in 2008. 
Serum hs-CRP (mg/L) was measured using the Olympus AU640 chemistry analyser (Olympus 
Diagnostics, United Kingdom).  
Analytical models 
The association between vascular risk factors and the subsequent risk of PMR and GCA was 
estimated using hazard ratios in a multivariate Cox proportional hazards regression model.  The 
model included age at recruitment to the cohort, sex, BMI, smoking status, diastolic blood pressure, 
serum lipid and hs-CRP levels as covariates.  A clinically relevant cut-point were chosen for LDL at 3 
mmol/L in line with UK guidance.  Diastolic blood pressure was dichotomised at 90 mm/Hg to create 
a category of raised diastolic blood pressure, a recognised risk factor for peripheral arterial disease 
(11). The ranges for hs-CRP were chosen as <1 mg/L, 1 to 3 mg/L and >3 mg/L be consistent with 
other published studies including the Women’s Health Study (12).  There were too few cases of 
diabetes among the cohort for this to be included as a covariate in the model.  A sensitivity analysis 
was used to investigate the potential influence of misclassification of disease status, with analysis 
limited to those cases of PMR and GCA which fulfilled the EULAR/ACR criteria for PMR (13) and 1990 
ACR criteria for GCA (14).  All analyses were carried out using STATA Version 12.1.  
Ethical considerations 
The study complies with the Declaration of Helsinki.  The Norwich District Health Authority Ethics 
Committee approved the study and participants gave written informed consent. 
 
Results 
The study included a total of 315,022 person years of follow up.  During this period of observation, 
there were 395 individuals with incident PMR and 118 with incident GCA.  Individuals classified as 
having GCA, 43 presented with either co-existing or preceding PMR.  The characteristics at 
enrolment of those patients with a final classification of PMR and GCA are shown in Table 1.  The 
mean length of follow-up between enrolment and the diagnosis for PMR was 10.8 years (SD 4.8 
years) and for GCA was 11.5 years (SD 4.8 years).  Similar proportions of those diagnosed with PMR 
and GCA were female (PMR 74.4%; GCA 74.6%). 
Multivariate modelling accounting for covariates showed raised diastolic blood pressure at time of 
enrolment to the cohort was associated with subsequent incident PMR, and ever-smoking was 
associated with incident GCA (Table 2).  The strongest associations were with advancing age and the 
female sex.  There was no consistent association with body mass index. There was an increase in the 
hazard ratio for those individuals with an hs-CRP >3 mg/L at enrolment and subsequent PMR, but 
the was not statistically significant when restricting to those individuals who met classification 
criteria. 
Model diagnostics including examination of Schoenfeld residuals supported the proportional hazards 
assumption. 
Limiting the analysis to those cases which fulfilled the current classification sets resulted in similar 
estimates of risk. The estimate for hs-CRP and incident GCA was strengthened (Table 2). 
Table 1 . Characteristics of the EPIC-Norfolk cohort at enrolment 
 Population who did not 
develop PMR or GCA (n 
= 25,147) 
PMR meeting clinical 
definition at 
subsequent diagnosis 
(n = 395) 
PMR meeting classification 
criteria at subsequent 
diagnosis (n = 272) 
GCA meeting clinical 
definition at 
subsequent diagnosis 
(n = 118) 
GCA meeting classification 
criteria at subsequent 
diagnosis (n = 76) 
Age at enrolment* 58.9 64.5 64.6 64.6 64.6 
Female, n (%) 13,670 (54.4) 294 (74.4) 204 (75.0) 88 (74.6) 57 (75.0) 
Never smoker, n (%) 11,443 (45.5) 197 (49.9) 139 (51.7) 47 (39.8) 30 (41.1) 
High Blood pressure†, n (%) 3,570 (14.2) 78 (19.8) 52 (19.2) 23 (19.5) 19 (25.0) 
Systolic BP (mm/Hg) (SD) 135 (18) 140 (20) 140 (20) 135 (16) 136 (17) 
Diastolic BP (mm/Hg) (SD) 83 (11) 84 (12) 84 (12) 82 (11) 82 (11) 
Diabetes†, n (%) 581 (2.3) 7 (1.8) 5 (1.8) 2 (1.7) 2 (2.6) 
BMI (kg/m2) (SD) 26.4 (3.9) 26.7 (3.9) 26.3 (3.6) 26.0 (3.7) 25.7 (3.5) 
Triglycerides (mmol/L)* 1.5 1.6 1.6 1.6 1.6 
HDL (mmol/L) (SD) 1.42 (0.43) 1.49 (0.42) 1.48 (0.40) 1.47 (0.42) 1.47 (0.38) 
LDL (mmol/L) (SD) 3.96 (1.03) 4.30 (1.16) 4.30 (1.13) 4.21 (1.09) 4.23 (0.96) 
hs-CRP (mg/L) (SD) 3.1 (6.3) 3.8 (7.4) 3.8 (7.6) 3.7 (6.0) 4.3 (7.1) 
*medians, otherwise arithmetic means and standard deviations are presented (SD), †Self-reported at baseline questionnaire. Self-reported diagnoses are from baseline 
questionnaire at time of recruitment. BP – Blood pressure, BMI – Body mass index, HDL – high-density lipoprotein, LDL – Low-density lipoprotein.  
Table 2. Vascular risk factors and their association to incident diagnoses of PMR and GCA using multivariate Cox proportional hazard modelling 
 
PMR PMR Classification set GCA GCA Classification set 
Total (n) 395 272 118 76 
     Age 1.11 (1.09, 1.13) p=<0.0001 1.11 (1.09, 1.13) p=<0.0001 1.12 (1.09, 1.15) p=<0.0001 1.11 (1.07, 1.15) p=<0.0001 
Sex (female) 2.11 (1.55, 2.87) p=<0.0001 2.14 (1.55, 2.30) p=<0.0001 2.04 (1.23, 3.40) p=0.006 1.94 (1.03, 3.67) p=0.041 
Ever smoking 1.13 (0.87, 1.47) p=0.373 1.11 (0.84, 1.46) p=0.466 2.01 (1.26, 3.20) p=0.003 1.81 (1.02, 3.24) p=0.044 
     
BMI      
<18.5 kg/m2 ref ref ref ref 
18.5 - 24.9 kg/m2 0.74 (0.34, 1.60) p=0.441 0.71 (0.33, 1.55) p=0.394 2.04 (0.28, 15.03) p=0.482 1.61 (0.22, 11.99) p=0.643 
25.0 - 29.9 kg/m2 0.83 (0.39, 1.79) p=0.637 0.76 (0.35, 1.64) p=0.487 2.22 (0.31, 16.14) p=0.431 1.10 (0.15, 8.20) p=0.923 
>30 kg/m2 0.67 (0.29, 1.50) p=0.316 0.58 (0.25, 1.34) p=0.206 1.04 (0.13, 8.54) p=0.967 0.76 (0.09, 6.35) p=0.799 
     
Diastolic Blood pressure >90 mm/Hg 1.35 (1.01, 1.80) p=0.045 1.39 (1.03, 1.88) p=0.033 0.93 (0.54, 1.60) p=0.789 1.29 (0.69, 2.41) p=0.425 
     
LDL >3 mmol/L 1.00 (0.67, 1.50) p=0.998 1.02 (0.67, 1.54) p=0.945 1.07 (0.53, 2.16) p=0.860 2.29 (0.71, 7.44) p=0.167 
     
hs-CRP bands     
<1 mg/L ref ref ref ref 
1 to <3 mg/L 1.31 (0.93, 1.83) p=0.122 1.21 (0.86, 1.71) p=0.269 0.71 (0.40, 1.24) p=0.227 0.65 (0.30, 1.41) p=0.279 
 >3 mg/L 1.45 (1.00, 2.10) p=0.049 1.33 (0.91, 1.94) p=0.143 1.29 (0.73, 2.28) p=0.378 1.93 (0.96, 3.88) p=0.067 
 
BMI – body mass index, LDL low-density lipoprotein, hs-CPR high sensitivity C-reactive protein.  
Discussion 
In common with other study designs which have examined the association of risk factors for incident 
PMR and GCA, our analysis has shown that advancing age and the female sex have the strongest 
association with the risk of onset of PMR and GCA.  Our data also show an association between 
established cardiovascular risk factors and disease onset: raised diastolic blood pressure (>90 
mm/Hg) increases the risk of onset of PMR, and smoking increases the risk of onset of GCA. 
Increased hs-CRP measured at enrolment was associated with an increased risk for subsequent 
development of PMR and GCA but the confidence intervals included values with a reduced risk and 
therefore no definite association can be concluded from these data. In the cohort as a whole, there 
is association between hs-CRP and the dichotomised diastolic blood pressure variable that that is 
independent of PMR and GCA, which is consistent with there being aetiological link between 
vascular disease and inflammation. For BMI the point estimates for risk show a reduced risk for PMR 
and GCA in those with a BMI of >30 kg/m2 but did not reach statistical significance. This contrast 
with a recent study in Sweden that showed a protective effect amongst those with obesity (15). 
Previous studies examining the association with cardiovascular factors in these two diseases have 
produced conflicting results (4) (16).  There is also uncertainty as to when the risk operates, and 
whether vascular disease is a cause or a consequence of PMR or GCA. 
A systematic review published in 2012, and a subsequent metanalysis carried out in 2017, concluded 
that the risk of cardiovascular disease is increased following a diagnosis of  PMR (17, 18).  In GCA, 
three separate meta-analyses have assessed risk. from different perspectives, using data from 14 
studies.  The conclusion was that smoking was a risk factor for GCA onset (19), and that peripheral 
arterial disease but not cardiovascular disease is increased in individuals following their diagnosis of 
GCA (2, 20).  These analyses included data from a mixture of case-control and cohort designs.  All 
reported substantial heterogeneity. 
The issue has also been addressed in large administrative datasets using nested case-control cohort 
designs.  Pujades-Rodriguez et al looked at 12 cardiovascular disease presentations in those with a 
diagnosis PMR, GCA or co-existing PMR with GCA using the CALIBER dataset. CALIBER is a bespoke 
dataset using participants within Clinical Practice Research Datalink (CPRD) linked to the Myocardial 
Ischaemia National Audit Project (MINAP), and Hospital Episode Statistics (HES) dataset and the 
Office for National Statistics (ONS) mortality and social deprivation data.  The analysis identified 
1,164 patients with GCA and 9,776 patients with PMR (4).  No association was found to 12 
presentations of vascular disease amongst those with PMR or GCA.  Using unlinked data relating to 
GCA alone from the same data source (CPRD), Li et al (16) showed an increased risk for vascular 
disease.  They also found an increased incidence of CVD events prior to the onset of GCA.  In both 
studies, those with PMR or GCA were more likely to have been prescribed blood pressure lowering 
medication and antiplatelet therapy than controls despite matching on age, sex and GP practice (4)  
(16). 
These large-scale studies based on administrative data did not apply classification criteria to their 
cases and may have resulted in an underestimate of risk.  Using disease end-points as opposed to 
risk factors for vascular disease potentially limits the power to assess vascular risk.  The strength of 
this study over register-based studies include the detailed case ascertainment, the population-based 
design, and the length of follow-up.  
Our study is limited by the relatively small number of incident cases of PMR and GCA.  Further, 
vascular risk factors were recorded at enrolment which might have led to an underestimate of risk.  
In addition, we are unable to assess for treatment of cardiovascular risk factors and how these might 
have modified risk.  A more robust biomarker of early vascular disease would allow these risks to be 
assessed with greater certainty. 
Conclusions 
This study shows that cardiovascular risk factors increase the risk of subsequent onset of PMR and 
GCA and indicate that vascular disease, PMR and GCA share common risk factors.  Early 
characterisation of vascular risk has the potential of reducing the future risk of these diseases 
amongst a patient population with significant comorbidity. 
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